1113 chmps
BioCentury & Getty Images

Regulation

BioMarin withdraws MAA for hemophilia gene therapy following safety, durability concerns

Nov 14, 2020 | 3:23 AM GMT

Among CHMP’s monthly roundup of opinions was an MAA withdrawal for BioMarin’s hemophilia gene therapy linked to EMA concerns about safety and

Read the full 445 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE